VYLDA 50 15'S

About

Vylda 50 (Vildagliptin 50mg) is an oral anti-diabetic agent from the dipeptidyl peptidase-4 (DPP-4) inhibitor class, specifically indicated for the treatment of type 2 diabetes mellitus. Its primary mechanism of action involves inhibiting the enzyme DPP-4, which leads to an increase in the levels of active incretin hormones, GLP-1 and GIP. These incretins play a crucial role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells and suppressing glucagon release from alpha cells in a glucose-dependent manner. This results in improved glycemic control by lowering both fasting and postprandial blood glucose levels.

Vildagliptin 50mg is often used when diet and exercise alone are insufficient, and it can be prescribed as monotherapy or in combination with other anti-diabetic medications, offering a favorable safety profile with a low risk of hypoglycemia when not combined with insulin or sulfonylureas.

Uses

• Management of type 2 diabetes mellitus.
• Improving blood glucose control.
• Reducing fasting and post-meal sugar levels.
• Used as monotherapy or in combination therapy.

Directions For Use

Take orally, usually once or twice daily, with or without food, as directed by your physician.

Benefits

• Effective in lowering blood glucose.
• Low risk of hypoglycemia as monotherapy.
• Weight-neutral effect.
• Improves both fasting and post-meal glucose.
• Enhances natural insulin release.
• Generally well-tolerated.

Side Effects

• Headache
• Dizziness
• Nausea
• Diarrhea
• Constipation
• Upper respiratory tract infection
• Nasopharyngitis
• Cough
• Peripheral edema
• Arthralgia (joint pain)
• Pancreatitis (rare)
• Liver enzyme elevation (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may affect blood sugar levels.
• Pregnancy - Vildagliptin is not recommended during pregnancy due to insufficient data on human safety. Insulin is usually preferred.
• Breastfeeding - It is advised to avoid Vildagliptin during breastfeeding as it may pass into breast milk. Consult a doctor.
• Liver - Vildagliptin is not recommended for patients with moderate to severe liver impairment due to potential for liver enzyme elevation.
• Kidney - Dose adjustment may be required in patients with moderate to severe kidney impairment. Consult your doctor.
• Lung - No specific contraindications or major safety concerns related to lung conditions are typically associated with Vildagliptin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.